The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | FIRE-6: avelumab + FOLFIRI plus cetuximab followed by avelumab maintenance in untreated RASwt mCRC
Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, discusses the results of the Phase II FIRE-6 trial which evaluated avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type (wt) colorectal cancer (CRC). With a median progression-free survival of 7.0 months, FIRE-6 did not reach its pre-specified endpoint. Avelumab maintenance after FOLFIRI plus cetuximab therefore is not effective to postpone disease progression after FOLFIRI plus cetuximab induction therapy in first-line RASwt mCRC patients.This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
